Jump to content

Perry Nisen

From Wikipedia, the free encyclopedia
Perry Nisen
BornJuly 27, 1955
NationalityAmerican
Alma materStanford, Albert Einstein College of Medicine
Known forCancer drug discovery and development, clinical trial data sharing, deletions by transposons, X-recessive disorders in females, molecular genetics of human cancers
Scientific career
FieldsMolecular Biology, Clinical Translation, Drug Discovery and Development, Clinical Data Sharing, Executive Management, Governance
InstitutionsSanford Burnham Prebys Medical Discovery Institute GlaxoSmithKline, Abbott Laboratories
Thesis Flexible Genomes: Observations on the Rearrangement of DNA Sequences
Doctoral advisorStanley Norman Cohen (pre-doctoral), Lucy Shapiro(doctoral)

Perry Nisen is an American physician and the former chief executive officer (CEO) of the Sanford Burnham Prebys Medical Discovery Institute (SBP).[1] He was appointed as CEO in August 2014, and held the Donald Bren Chief Executive Chair.[2]

Early life and education

[edit]

Career

[edit]

Before joining SBP, Nisen was Senior Vice President of Science and Innovation at GlaxoSmithKline (GSK). In this role, he facilitated innovation and integration of R&D across GSK's global organization and contributed to the discovery, development and commercialization of many drugs.[4] Earlier in his career at GSK, he held various key positions, including interim Chief Medical Officer, Senior Vice President and Oncology Therapy Area Head, Senior Vice President of Cancer Research, and Senior Vice President of Clinical Pharmacology and Discovery Medicine.[5]

Formerly, he was the Lowe Foundation Professor of Neuro-Oncology at the University of Texas Southwestern Medical Center. He headed a basic research laboratory and was a practicing physician in pediatric hematology-oncology. He was a member of the Genetics and Development Graduate Training Program.[3]

Awards and honors

[edit]

References

[edit]
  1. ^ "Sanford Burnham Prebys CEO Perry Nisen Retiring in September". Times of San Diego. 2017-08-10.
  2. ^ "Meet Sanford-Burnham's new CEO Perry Nisen". San Diego Union Tribune. 19 August 2014.
  3. ^ a b c "Perry Nisen, M.D., Ph.D. - SBP". www.sbpdiscovery.org.
  4. ^ Bender, Eric; Bender, E. (5 November 2015). "Q&A: Perry Nisen". Nature. 527 (7576): S18. Bibcode:2015Natur.527S..18B. doi:10.1038/527S18a. PMID 26536220.
  5. ^ "Perry D. Nisen M.D., Ph.D.: Executive Profile & Biography". Bloomberg. Archived from the original on 2017-08-23.